April 3, 2026 -- OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and expression solutions, today announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. This collaboration brings together OneCyte's proprietary single-cell platform for high-throughput, high-sensitivity, and high-speed clone selection with Kemp Protein

April 2, 2026 -- LOTTE HOLDINGS, CO., LTD. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE HOLDINGS”) announces a strategic investment into Rakuten Medical, Inc. (hereinafter “Rakuten Medical”), a global biotechnology company developing and commercializing photoimmunotherapy-based anticancer therapies through its proprietary Alluminox ® platform. Founded in 2010 and headquartered in San Diego, CA, Rakuten Medical is currently advancing ASP-1929, its first photoimmunotherapy drug, thro

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D17 total score compared to placebo at hour 60 (primary endpoint); the primary endpoint was not met In a post hoc analysis of participants (n=54) who had a history of psychiatric conditions, LPCN 1154 demonstrated nominal statistically significant and clinically meaningful reductions in HAM-D scores compared to placebo as early as hour 12 and sustained th

Research published in Molecular Therapy Nucleic Acids demonstrates broad biodistribution and controlled PMP22 silencing, supporting advancement toward human trials Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy Nucleic Acids describing the safety and biodistribution impact of TVR110, a first-in-class and potential best-in-class vectorized microRNA i

April 3, 2026 -- Syneron Bio, a leader in intelligent platform-driven macrocyclic peptide drug discovery, announced the successful closing of its Series B financing on March 31th. The round was led by an international life-science fund, with co-lead participation from Decheng Capital, and CDH VGC. Additional investors included a wholly owned subsidiary of the Abu Dhabi Investment Authority ("ADIA"), True Light Capital, — an independent, wholly-owned subsidiary of Temasek, Qiming Venture Partners

Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company pioneering optogenetic therapies for those living with retinal degenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, RTx-015, for the treatment of retinitis pigmentosa (RP). "Receiving RMAT designation is a critical step as we move along the continuum of progress toward bringing hope to patients with a

Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment of a serious or life-threatening condition April 01, 2026 -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration

April 1, 2026 -- Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporation, today announced the finalization of the transfer of the RADICAVA (edaravone) business to Shionogi Inc. (SI). TPA previously announced the transfer on December 22, 2025. This critical milestone ensures continued strength and strategic alignment for RADICAVA, a leading therapy for amyotrophic lateral sclerosis (ALS). Effective immediately, the RADICAVA business, including intellectual pro

Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial Study published in Frontiers in Pain Research reports significant reduction in knee pain with topical curcumin formulation April 1, 2026 -- Vascarta Inc. today announced the publication of results from a randomized, double-blind, placebo-controlled clinical trial evaluating VAS-101, the company's investigational topical/transdermal curcumin gel, for the treatment of knee pa

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for A2B543, an autologous CAR T-cell therapy designed for the treatment of germline heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express MSLN and have lost HLA-A*02 expression. Fast Track is a pro